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Opposing calcium-dependent signalling pathways
control skeletal muscle differentiation by regulating
a chromatin remodelling enzyme
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Calcium signalling is important for differentiation-dependent gene expression, but is also
involved in other cellular functions. Therefore, mechanisms must exist to distinguish calcium
signalling relevant to differentiation. Calcineurin is a calcium-regulated phosphatase that is
required for myogenic gene expression and skeletal muscle differentiation. Here, we
demonstrate that inhibition of calcineurin blocks chromatin remodelling and that the Brg1
ATPase of the SWI/SNF chromatin remodelling enzyme, which is required for the activation
of myogenic gene expression, is a calcineurin substrate. Furthermore, we identify the
calcium-regulated classical protein kinase C b (PKCb) as a repressor of myogenesis and as
the enzyme that opposes calcineurin function. Replacement of endogenous Brg1 with a
phosphomimetic mutant in primary myoblasts inhibits myogenesis, whereas replacement
with a non-phosphorylatable mutant allows myogenesis despite inhibition of calcineurin
signalling, demonstrating the functionality of calcineurin/PKC-modified residues. Thus, the
Brg1 chromatin remodelling enzyme integrates two antagonistic calcium-dependent signalling
pathways that control myogenic differentiation.
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A
TP-dependent SWItch/Sucrose NonFermentable (SWI/
SNF) chromatin remodelling enzymes are large, multi-
protein complexes that are capable of rendering a closed,
repressive chromatin structure into an open, transcriptionally
competent configuration by altering contacts between DNA and
histones1. SWI/SNF activity is required for the activation of a
large number of genes during development, and has also been
implicated in basic cellular functions including replication2,3 and
DNA repair4. Mutations in SWI/SNF components have been
shown to occur frequently in various cancers5,6, and have also
been implicated in other human diseases7.
Given the broad range of functions for SWI/SNF, the activity of
the complex must be regulated in such a way as to direct its
activity both spatially and temporally. One mechanism by which
this can be accomplished is by changing the properties of
SWI/SNF through its specific subunit composition. Variations in
subunit composition have been shown to be important for
specific developmental programmes, including myogenesis8,9.
However, selection of the catalytic subunit, which can be Brahma
(Brm) or Brahma Related Gene 1 (Brg1), provides the most
striking difference in function. The two ATPases have similar
chromatin remodelling activities in vitro10, but mouse modelling
approaches have demonstrated that Brg1 is necessary for early
embryogenesis and most tissue differentiation events11–13,
whereas Brm knockout mice exhibited no clear defects14.
Subunit composition alone, however, cannot fully explain how
SWI/SNF enzymes are coordinated to remodel chromatin at
specific chromosomal loci in response to signalling cues. To
accomplish this, SWI/SNF enzymes likely are responsive to signal
transduction through post-translational modification. Indeed,
most of the subunits are phosphoproteins15, and phosphorylation
of the SWI/SNF subunit Baf60c by the p38 mitogen-activated
protein kinase is required for the assembly of the enzyme
complex at myogenic promoters8,16. Given the diversity of
SWI/SNF subunit composition and the potential for significant
post-translational modification, clear evidence for the enzyme
complex as a target of multiple signal transduction pathways
would identify chromatin remodelling as a key step in translating
widely used signal transduction pathways into diverse but specific
transcriptional responses.
The calcium-sensitive serine/threonine phosphatase calci-
neurin has been shown to be necessary for differentiation of
immortalized rat and primary human myoblasts and for
regeneration of damaged muscle in mice in-vivo17,18.
Calcineurin function via control of the sub-cellular localization
of the NFAT transcription factor is well-established in other
tissue types19. However, prior work has revealed a more
complicated role for calcineurin in skeletal muscle that likely
involves other, yet uncharacterized mechanisms of action20.
More recent studies showing an interaction of SWI/SNF with
calmodulin, a component of calcineurin, and a calcium-
dependent step in SWI/SNF-mediated chromatin remodelling21
raised the possibility that SWI/SNF enzyme might be a target of
calcineurin. Because both calcineurin and SWI/SNF have been
shown to be required for activation of genes in muscle
differentiation, we investigated connections between calcineurin
and SWI/SNF enzymes. We show that inhibition of calcineurin
blocks chromatin remodelling, myogenic gene expression and
myogenic differentiation. We identify protein kinase C bI
(PKCbI) as a repressor of myogenesis and as the kinase that
opposes calcineurin function. These enzymes temporally regulate
the phosphorylation state of the Brg1 ATPase that controls
SWI/SNF chromatin remodelling enzyme activity. This work
supports the novel conclusion that SWI/SNF enzyme acts as an
integrator for two opposing calcium-sensitive pathways, the
balance of which regulates skeletal muscle differentiation.
Results and Discussion
Calcineurin regulates Brg1 during myogenic differentiation.
We sought to investigate whether calcineurin signalling impacted
SWI/SNF chromatin remodelling function and its essential role in
skeletal myogenesis. First, we verified that inhibition of calci-
neurin, either with the drug FK506 (ref. 22) or by overexpression
of the calcineurin inhibitory peptide (CAIN)23, blocked
differentiation of C2C12 myoblasts and induction of myogenin
(Supplementary Fig. 1a) and Myosin Heavy Chain (MyHC,
Supplementary Fig. 1b), without altering levels of MyoD
(Supplementary Fig. 1c). Because it is difficult to separate the
effect of loss of myogenin activity and possible effects of
calcineurin on the later stages of myogenic gene expression,
which are myogenin dependent, we focused our search for
additional targets of calcineurin on the myogenin promoter. It is
known that Brg1 remodels chromatin to facilitate myogenin
activation24,25 and that Brg1 is inactivated by hyper-
phosphorylation during mitosis26, making it a potential target
for activation by phosphatase activity. We therefore examined the
Brg1-dependent chromatin remodelling of the myogenin
promoter in the presence of FK506, and found that inhibition
of calcineurin activity by FK506 led to a loss of chromatin
remodelling activity (Fig. 1a) as well as loss of Brg1 binding at the
myogenin promoter (Fig. 1b), suggesting that calcineurin activity
is required for the interaction of the SWI/SNF ATPase with
chromatin in differentiating cells. Furthermore, reciprocal
co-immunoprecipitations (co-IPs) showed an interaction
between calcineurin and the Brg1-containing SWI/SNF complex
(Fig. 1c).
Because Brg1 is a nuclear protein, interaction with calcineurin
should occur within the nucleus. Epifluorescent images of
confluent C2C12 cells stained for calcineurin showed cytoplasmic
staining with nuclear foci (Supplementary Fig. 2a). Addition of
Leptomycin B resulted in nuclear accumulation, demonstrating
active shuttling of calcineurin between the nucleus and the
cytoplasm (Supplementary Fig. 2b). Some co-localization of Brg1
and calcineurin in nuclear foci was observed (Supplementary
Fig. 2c,d), supporting the co-IP data. We also investigated Brg1
and calcineurin co-localization in sub-confluent proliferating
cells, but saw no clear difference from the co-localization seen in
confluent cells (Supplementary Fig. 2e).
These data raised the possibility that calcineurin is capable of
binding chromatin. Chromatin immunoprecipitation (ChIP)
experiments showed that calcineurin was bound to the myogenin
promoter even in proliferating cells (Fig. 1d) as shown by a
significant increase in pull-down compared with the IgG control.
Calcineurin binding increased soon after differentiation began
(Fig. 1d; 1.5 h). This increase in binding corresponded to
co-occupation of the promoter by both calcineurin and Brg1
as shown by sequential, or re-ChIP, experiments (Fig. 1e),
suggesting that the two proteins form a stable complex on
chromatin in differentiating cells.
As calcineurin is a phosphatase, it is expected that a target
protein would be hyperphosphorylated in cells treated with a
calcineurin inhibitor. To examine calcineurin-sensitive Brg1
phosphorylation, we utilized an indirect mass spectrometry
(MS) method that allows for inference of a peptide’s phosphor-
ylation state (Supplementary Fig. 3a)27. Using this method on
immunoprecipitated Brg1, tryptic peptides covering 31.6% of the
length of Brg1 were identified (Supplementary Table 1). Analysis
of the phosphorylation state of Brg1 revealed that peptides from
dimethylsulphoxide (DMSO)-treated cells showed no differences
between potentially phosphorylated peptides (those containing
serine, threonine or tyrosine (STY)) and those that cannot
be phosphorylated (non-STY)). However, peptides from Brg1
isolated from FK506-treated cells showed a significant difference
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in labelling between STY and non-STY peptides, suggesting
hyper-phosphorylation in the absence of calcineurin activity
(Fig. 1f).
PKCbI phosphorylates Brg1 and represses myogenesis. The MS
data were then used to predict which kinase might be responsible
for Brg1 hyperphosphorylation in the FK506-treated sample.
For each peptide, the likely presence or absence of a site for 16
different kinases was determined using NetPhosK28. The kinase
predictions for protein kinase C (PKC) are included in
Supplementary Table 1 (right-most column). We then used the
relative abundance of the non-phosphorylated peptide divided by
the total amount of peptide as an indication of the extent of
phosphorylation of each peptide. When the peptides were sorted
by phosphorylation score (columns 7 and 9, Supplementary
Table 1), those with potential PKC sites clustered near the top
of the list (Supplementary Fig. 3b). We performed a logistic
regression to look for an association between peptide
phosphorylation and the predicted presence of a kinase site as
identified by NetPhosK28. There was a statistically significant
association for PKC (P¼ 0.04), but not for any of the other
kinases examined (Supplementary Fig. 3b). This suggests that
PKC might be a kinase involved in Brg1 phosphorylation. We
note that had we obtained greater coverage of Brg1, it is likely that
additional kinases would have been identified as candidate
kinases. This should be expected, as Brg1 has long been known
as a heavily phosphorylated protein26,29,30, not all peptides that
we detected were sensitive to the calcineurin inhibitor, suggesting
that other phosphatases and perhaps other kinases are relevant,
and indeed other kinases have been implicated as regulating Brg1
phosphorylation26,29.
If PKC is responsible for phosphorylating calcineurin target
sequences, then inhibition of PKC should relieve the repression of
myogenesis caused by calcineurin inhibition. We found that the
drug Go6976, which inhibits the activity of the calcium-sensitive
classical PKC isoforms31, restored both myogenin (Fig. 2a,b) and
MyHC (Fig. 2c,d) expression in cells treated with FK506 or in
cells overexpressing CAIN (Supplementary Fig. 4a). In addition,
the expression of other marker genes, including acetylcholine
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Figure 1 | BRG1 is a calcineurin target. (a) 24 h post differentiation, the accessibility of a PvuII site in the myogenin promoter increased as measured by
restriction enzyme accessibility. In the presence of FK506, this increase in accessibility was lost. P-values were determined by a two-tailed unpaired t-test.
(b) ChIP showed that binding of Brg1 to the myogenin promoter occurred after cells became confluent, increased during differentiation and was lost upon
FK506 treatment. P-values below the graph indicate the significance of the increase over IgG control using a one-tailed paired ratio t-test; P-values above
represent significant differences in the magnitude of binding (Brg1/IgG) as determined by a two-tailed unpaired t-test. (c) Reciprocal co-IPs showed that a
calcineurin antibody immunoprecipitated Brg1, and antibodies against SWI/SNF subunits precipitated calcineurin from differentiating C2C12 lysates.
(d) ChIP demonstrating that calcineurin bound to the myogenin promoter at all time points tested, as shown by a significant increase in binding compared
with IgG (P-values as described in a are shown below the graph). By 1.5 h post differentiation, there was a further increase in calcineurin binding (two-tailed
unpaired t-test). (e) Sequential ChIPs (re-ChIPs) showed co-occupancy by Brg1 and calcineurin by 1.5 h post differentiation. The graph shows the results for
the Brg1 then Cn re-ChIP. P-values shown beneath the graph are one-tailed paired ratio t-tests for an increase in binding using the antibody orders described
compared with control samples immunoprecipitated with IgG as the second antibody. Data in quantified experiments reflect averages of three independent
experiments each run in duplicate±s.d. (f) Using differential iTRAQ labelling, the abundance of each non-modified peptide obtained from trypsin-digested
Brg1 isolated from differentiating C2C12 cells was compared with the abundance of the same sequence present in the half of the sample that had been
subjected to in vitro dephosphorylation. This indirectly provides quantification of the phosphorylated fraction of each peptide. Brg1 from DMSO-treated cells
showed equivalent ratios of isobaric labelling between non-phosphorylatable (non-STY) and phosphorylatable (STY) peptides. Using a two-tailed t-test,
Brg1 from FK506-treated cells showed a statistically significant difference between these two groups, indicating hyperphosphorylation of Brg1 in the
absence of calcineurin activity.
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receptor and Caveolin 3, confirmed that FK506 sensitivity was
reversed by treatment with Go6976 (Fig. 2e,f). These results
indicate for the first time that the calcium-sensitive PKCs inhibit
myogenesis, and that an additional calcium-dependent signal,
calcineurin, is required to relieve this repression.
We next sought to determine whether repression of myo-
genesis by PKC is mediated through Brg1. This idea was
supported by the fact that PKC was able to phosphorylate
purified recombinant Brg1 in-vitro, and this phosphorylation was
inhibited in a dose-dependent manner by the addition of purified
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Figure 2 | PKC antagonizes calcineurin function. (a,b) The classical PKC inhibitor Go6976 restored myogenin expression in FK506-treated C2C12 cells
as shown by immunofluorescence staining and confirmed by counting of stained nuclei. Five fields for each sample were counted for each of three
independent experiments. Data represent the average±s.d. P-values were determined by a two-tailed t-test. Size bars, 100mm. (c,d) Myosin heavy chain
(MyHC) expression was similarly restored as shown by immunocytochemistry and western blotting. Size bars, 100mm. (e,f) Inhibition of classical PKC
activity by treatment with Go6976 rescued mRNA expression of additional myogenic genes, including acetylcholine receptor (AchR) and Caveolin 3
(Cav3). The data represent the average of three independent experiments each run in triplicate ±standard deviation. The values from the subconfluent
(Subconf) samples were set to 1. The P-values represent two-tailed t-tests for differences between samples indicated. (g) PKC phosphorylated recombinant
FLAG-tagged Brg1 as shown by 32P autoradiography. Calcineurin addition inhibited Brg1 phosphorylation by PKC. Quantified data represent the average of
three independent experiments±standard deviation. Two-tailed t-tests showed a significant increase in phosphorylation when Brg1 was treated with PKC,
and this phosphorylation decreased when calcineurin was added. A western showing equal loading of FLAG-Brg1 is displayed below the autoradiograph.
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calcineurin (Fig. 2g). There are three classical PKCs known to be
inhibited by the drug Go6976: PKCa, PKCb, which has two splice
variants, PKCbI and PKCbII, and PKCg31. All require both a
phospholipid ligand, usually diacylglycerol (DAG), and increased
calcium concentrations for activity32. The proximity ligation
assay33 was used to examine interactions between PKC isoforms
and Brg1 (Fig. 3a–d). This assay is advantageous because it shows
protein–protein interactions in their native context and alleviates
the problem of ligand removal during extraction. We identified
interactions between Brg1 and PKCbI when cells were sub-
confluent (Fig. 3b–d). This is notable because it suggests that the
interaction between PKCbI and Brg1 exists before the
differentiation-induced activation of myogenic gene expression,
which is a Brg1-dependent process. The PKCbI interaction with
Brg1 is consistent with the fact that we could readily detect
PKCbI in the nucleus (Supplementary Fig. 4b), while PKCa
staining was cytoplasmic (Supplementary Fig. 4c). PKCg was also
found in the nucleus (Supplementary Fig. 4d), despite its lack of
interaction with Brg1. Two different short hairpin RNAs
(shRNAs) that knock down PKCb protein levels in C2C12 cells
(Supplementary Fig. 5a) partially restored both myogenin and
MyHC (Supplementary Fig. 5b) expression in the presence of
FK506, complementing the PKC inhibitor studies and further
demonstrating that in the absence of PKCb activity, the need for
calcineurin activity was reduced.
We next sought to determine whether PKC/Brg1 interactions
and the potential negative effect of PKC phosphorylation on Brg1
could be observed at chromatin. PKCbI was not bound to the
myogenin promoter in proliferating cells, but was bound to the
myogenin promoter when cells became confluent (Fig. 3d), with a
notable decrease after differentiation began (1.5 h; Fig. 3e). This
binding is consistent with PKCbI being brought to the promoter
along with Brg1 recruitment in confluent cells (Fig. 1b), and was
confirmed by sequential ChIP experiments (Fig. 3f). Taken
together, these results suggest that Brg1 is associated with PKCbI
when recruited to the myogenin promoter in confluent cells but
PKCbI binding is quickly reduced, possibly due to the activity of
calcineurin, which is already present at the promoter (Fig. 1d).
Failure to detect co-binding of PKCbI and calcineurin to the
same chromatin fragments by re-ChIP (Supplementary Fig. 5c)
suggests mutually exclusive binding or that any possible
intermediate structure containing PKCbI, Brg1 and calcineurin
is quickly resolved with the loss of PKCbI from the promoter.
When combined with the observation that Brg1/PKCbI interac-
tion is reduced in confluent cells (Fig. 3a–d), these data support
the idea that while overall interaction between Brg1 and PKCbI is
reduced as Brg1 is brought to the promoter, sufficient interaction
remains to bring PKCbI to the promoter, where the interacting
proteins can still be detected by the very sensitive re-ChIP assay.
Promoter binding by PKCbI may play a role in preventing
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Figure 3 | PKCb interacts with Brg1 and blocks differentiation. (a–d) Proximity ligation assay (PLA) was used to detect in-situ interactions between Brg1
and PKC. Representative photomicrographs showing PLA signal (green) and 4,6-diamidino-2-phenylindole staining (blue) are shown of no-PKC antibody
controls (a), subconfluent cells with visible nuclear spots (b) and confluent cells (c). The number of nuclear spots was quantified by counting the number
of spots per nucleus in 50 nuclei per sample in two independent experiments. Size bars, 5 mm. (d) A statistically significant difference (Po0.0001;
Mann–Whitney test, uncorrected P-value) in the number of signals per nucleus for Brg1 and PKCbI in subconfluent cells was observed when compared with
Brg1 antibody alone. Interaction between HDAC2 and MyoD52–54 was included as a positive control. (e) PKCbI bound to the myogenin promoter in C2C12
cells at the onset of differentiation, but binding decreased as differentiation proceeded (P¼0.03; two-tailed unpaired t-test). The P-values listed below the
graph represent one-tailed paired ratio t-tests to test for a significant increase in pulldown compared with IgG in the same experiment. (f) Co-binding of
Brg1 and PKCbI occurs as cells became confluent as shown by reciprocal re-ChIPs. The graph represents the values from the Brg1 followed by PKCbI
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duplicate ±s.d.
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Brg1 from stably binding until signalling through calcineurin
occurs.
PKC target residues flank the Brg1 bromo domain. To address
the possible function of PKC phosphorylation on Brg1, we
identified Brg1 residues that could be phosphorylated by PKC.
An initial search for functional PKC sites utilized glutathione
S-transferase (GST) fusions across the length of Brg1
(Supplementary Fig. 6a) and identified two C-terminal fragments
(#5, #6) flanking or containing the bromodomain that could be
phosphorylated by PKC in-vitro (Supplementary Fig. 6b–d).
Mutations of these two fragments identified amino acids 1,620
(Supplementary Fig. 6e), 1,617 (Supplementary Fig. 6f), 1,409/10
(Supplementary Fig. 6g) and multiple amino acids between 1,417
and 1,430 (Supplementary Fig. 6g) as targets of PKC phosphor-
ylation. Mutation of an independent fragment comprising
fragments #5 and #6 and the carboxyl terminus confirmed
these results; mutation of 1,409/10 and 1,617/20 reduced the
phosphorylation of this fragment (Fig. 4a), and deletion of the
multiple serine/threonine containing region 1,417–1,430 further
reduced phosphorylation (Fig. 4a).
We attempted to detect phosphorylation of these peptides
directly using TiO2 phospho-peptide enrichment followed by
detection by MS. A phosphopeptide was identified corresponding
to the 1,417–1,430 region (Supplementary Fig. 7a–c). The MS/MS
spectrum indicates that this peptide is most likely phosphorylated
on Serine 1,421 or 1,422, however, it should be noted that the
Mascot Delta Ion Score34 is 0, indicating it is not possible to
distinguish between the multiple potential phosphorylation sites
on this peptide. The retention and mass coordinates of the
peptide were used to identify the location of the phosphopeptide
in the ion chromatograph of total Brg1 samples from FK506- or
DMSO-treated cells. The peaks were quantified and a significant
difference was observed between FK506- and DMSO-treated
cells (Fig. 4b), indicating hyperphosphorylation of this fragment
in calcineurin-inhibited cells. The identification of Brg1
phosphopeptides that include amino acids between 1,410 and
1,430 in the PhosphoSitePlus database35 provides additional
evidence that phosphorylation of this region occurs in a number
of systems and may have broad implications for control of Brg1
function.
Alignment of Brg1 and the closely related Brm enzyme reveal
that these sites are highly conserved in Brg1 from fish to humans,
but are not present in Brm (Fig. 4c). This suggests that the ability
to be phosphorylated by PKC is a trait unique to Brg1. Given the
essential role of Brg1 in differentiation and the dispensability of
Brm for mouse development and viability14, PKC regulation of
Brg1 may be one of the important functional differences between
these two otherwise similar proteins.
The identification of phosphorylation sites in this region
implies a regulatory function for this region, either through
association of Brg1 with other factors or through modulation of
Brg1 activity. To test the significance of Brg1 phosphorylation in
myogenesis, we sought to replace endogenous Brg1 with full-
length, Yellow Fluorescent Protein (YFP)-tagged, wild-type
Brg1 (WT-Brg1) or the C-terminal phosphomimetic (SE-Brg1)
or non-phosphorylatable (SA-Brg1) mutants described above
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Figure 4 | Amino acids (aa) flanking the Bromo domain of Brg1 are phosphorylated by PKC. (a) Mutation of aa 1,409/1,410 and aa 1,617/1,620 to
alanine significantly reduced the phosphorylation of a C-terminal Brg1 fragment (aa 1,360–1,647) by PKC. Further deletion of aa 1,417–1,430 reduced
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(b) A phospho-peptide containing aa 1,417-1,430 was identified by mass spectrometry and quantified from the extracted ion chromatogram. The graph
shows that the normalized abundance of the peptide was increased in the absence of calcineurin signalling. P-values in a, b are the result of two-tailed
t-tests. (c) Alignment of the PKC phosphorylated region of Brg1 between mouse (mm), human (hs), chicken (gg), zebrafish (dr) and Drosophila (dm) Brg1
and Brm showed a number of serine and threonine residues that are conserved among Brg1 homologues, but not with the paralogous regions of Brm. Black
bars beneath the alignment show regions identified as phosphorylated by PKC.
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(Supplementary Fig. 8a). We were unable to generate Brg1-
deficient C2C12 cells; instead we isolated satellite cells from mice
homozygous for a conditional Brg1 allele11 that could be removed
by Cre recombinase. These cells were propagated in culture and
infected with a mCherry-expressing retrovirus, in which
exogenous, YFP-tagged Brg1 would replace mCherry only after
recombination of the integrated retroviral vector by Cre
(Supplementary Fig. 8b). Thus, exogenous, YFP-labelled Brg1
would stably replace the endogenous protein in the presence of
Cre recombinase (Supplementary Fig. 8c).
Previous studies utilized Cyclosporin A (CsA) as an effective
inhibitor of calcineurin activity and differentiation in primary
human myoblasts36 and in in-vivo muscle regeneration in
mouse36. We found that in primary satellite cell cultures,
inhibition of calcineurin through administration of CsA
resulted in inhibition of myotube formation (Supplementary
Fig. 8d). Expression of CAIN also inhibited myogenesis in
primary myoblasts, with a similar reduction in myotube length
and nuclei content, but without loss of myogenin or MyHC
expression (Supplementary Fig. 8e). Unlike CsA-treated cells,
however, CAIN-expressing cells exhibited increased cell death
upon differentiation. Addition of Go6976 resulted in accelerated
differentiation (Supplementary Fig. 8f). These results suggest that
PKC activity blocks myoblast fusion and reinforce the idea that
PKC opposes calcineurin function in primary satellite cell-derived
myoblast cultures.
For each form of Brg1, wild type (WT-Brg1), phosphomimetic
(SE-Brg1) and non-phosphorylatable (SA-Brg1), we generated
mCherry-positive clones that differentiated well in the absence of
Ad-Cre and that expressed YFP in the nuclei of 495% of cells
when exposed to Ad-Cre (Supplementary Fig. 8g). Cre-induced
replacement of endogenous Brg1 with WT-Brg1 did not affect
myogenesis (Fig. 5a, top left) compared with untreated controls
(Supplementary Fig. 8h). Furthermore, the number of nuclei per
myotube did not differ between myotubes from Cre-treated and
untreated cultures (Fig. 5b). Cells expressing WT-Brg1 were also
sensitive to CsA treatment, which resulted in the formation of
myotubes that failed to elongate (Fig. 5a, top right, arrowheads),
and had significantly fewer nuclei (Fig. 5b). This phenotype was
mimicked by replacement of endogenous Brg1 with SE-Brg1.
Before administration of Ad-Cre, SE-Brg1 clones differentiated
normally as judged by the number of nuclei per myotube (Fig. 5b,
middle), whereas Cre-induced replacement of Brg1 resulted in
unfused cells, shortened, rounded myotubes (Fig. 5a, middle-left,
arrowheads), and a significant reduction in the number of nuclei
per myotube (Fig. 5b). These results were not further affected by
the presence of CsA (Fig. 5a, middle). Replacement with the non-
phosphorylatable SA-Brg1 did not significantly affect myotube
formation (Fig. 5a, bottom), or the number of nuclei per myotube
(Fig. 5b). Furthermore, treatment of these cells with CsA neither
impaired myogenesis (Fig. 5a, bottom-right) nor reduced nuclei
content (Fig. 5b), showing that the effect of CsA is mediated by
hyper-phosphorylation of Brg1. Similar results were found in
myoblasts expressing the CAIN inhibitor (Supplementary Fig. 8i).
Cells expressing WT-Brg1 or SA-Brg1 in the absence of CAIN
differentiated and formed myotubes with similar numbers of
nuclei per myotube. Cells expressing WT-Brg1 responded to
CAIN expression with a decrease in myotube length and number
of nuclei per myotube compared with cells infected with empty
vector. In contrast, cells expressing SA-Brg1 formed longer
myotubes with more nuclei per myotube, as expected.
A model for PKCbI/calcineurin function. Our results identify
PKCb as a regulator of myogenesis that functions in opposition to
calcineurin and indicate that PKC and calcineurin act by
modifying Brg1. Calcium signalling is common to many differ-
entiation pathways as well as a variety of cellular functions,
including cell cycling.37 It is not surprising, therefore, that
mechanisms exist to differentiate calcium signalling events that
relate to a specific function. Our data provide evidence for a
model in which regulation of SWI/SNF function is passed from
one calcium-sensitive pathway to another through modification
of the enzymatic subunit Brg1 (Fig. 5c). In subconfluent,
proliferating myoblasts, Brg1 is bound by PKCbI (Fig. 3b,d),
but is not bound to chromatin (Fig. 3e). Meanwhile, calcineurin is
in contact with the promoter, but is not yet strongly bound
(Fig. 1d). Because there are no reports of calcineurin having
independent DNA-binding activity, it is presumed to bind
through an as yet unknown partner. Once cells become
confluent and begin to differentiate, SWI/SNF is recruited to
the myogenin promoter (Fig. 1b) with PKCbI (Fig. 3e; 0 h).
Whether there is a short-lived intermediary structure or whether
Brg1/PKCbI can only bind to promoters unoccupied by
calcineurin remains to be determined, but within the first 1.5 h,
the promoter is predominantly occupied by Brg1/calcineurin. We
propose that the ability of calcineurin to dephosphorylate Brg1
promotes its positive activity in promoting differentiation.
The nature of the switch between the inhibitory effects of
PKCbI and its reversal by calcineurin remains to be elucidated.
One possibility is the presence of DAG, the PKC ligand, in the
nucleus accounts for the activity of PKCbI, which gives way to
calcineurin due to decreases in nuclear DAG. DAG is derived
from phospholipids and is normally considered a cell membrane
component, but it is also found in a variety of nuclear
compartments including splicing speckles and chromatin38.
Furthermore, nuclear forms of the enzymes responsible for
DAG production, such as phospholipase C39,40, and inactivation,
such as DAG kinase41, are found in the nucleus and have been
shown to impact differentiation of muscle cells. In addition to
potential changes in DAG signalling, the calcium signal itself may
contribute to differential activation of calcineurin and PKCb. The
existence of both of these proteins in the nucleus suggests that
nuclear calcium content may control transcriptional activity. The
existence of calcium transients in the nucleus has been confirmed
by the use of nuclear localized calcium reporters42,43, but the
source of the calcium influx has not yet been determined.
Differences in spatial pattern, duration or amplitude of the signal
may all play a role in differentially activating calcineurin and
PKCb.
We suggest that Brg1 acts as a nexus through which opposing
calcium-dependent signals controlling differentiation exert their
effects. The identification of Brg1, which provides catalytic
activity to the SWI/SNF enzyme and is required for most tissue
differentiation events, as a target of multiple signal transduction
pathways suggests a common mechanism by which these distinct
pathways are integrated and balanced to exert control over the
expression of differentiation-specific genes. The regulation of
Brg1 function is potentially complemented by a more specific
level of SWI/SNF enzyme regulation by signalling pathways, as
the cardiac- and skeletal muscle-specific SWI/SNF subunit,
Baf60c, has also been identified as a key target of the p38
MAP kinase pathway during differentiation8,16. Thus, signal
transduction-mediated regulation of the function of the more
ubiquitous catalytic subunit may be further refined by additional
signal transduction-mediated control of the function of a tissue-
specific enzyme subunit. The importance and specificity of this
regulatory mechanism are highlighted by the identification of
residues unique to Brg1 that are not found in its closely related
but dispensable homologue, Brm. Thus, the ability to be targeted
by signal transduction pathways may be an important functional
difference between these two similar ATPases. In conclusion, the
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data support the idea that Brg1 and the SWI/SNF complex as a
whole, is a critical target for integrating distinct signalling cues
during cellular differentiation.
Methods
Generation of plasmids. GST–Brg1 fusions were made by amplifying fragments
of Brg1 from pBluescript Flag-Brg1 (ref. 44) using the primers listed in
Supplementary Table 2 and cloning them into pGEX-2T. Mutations of fragments
#5, #6, and the C-term fragment were generated using the Quickchange Lightning
Multi-site Directed Mutagenesis kit (Agilent) using primers listed in
Supplementary Table 2. Mutations were verified by sequencing.
To make full-length mutant Brg1, the ClaI fragment was excised from
pBluescript Flag-Brg1 (ref. 44), blunted, and cloned into the EcoRV site of pCR3.1
(Invitrogen). The BssHI site in the pCR3.1 vector was then removed by excising the
fragment containing the neomycin-resistant gene using StuI and BstBI. The
mutated C-term fragments were then cloned into full-length pCR3.1-Brg1 using
BssHI and SalI restriction sites. The wild-type and mutant Brg1 sequences were
fused to YFP by cutting the NheI-BamHI fragment out of the EYFP-c1-Brg1
(ref. 45; gift of Gordon Hager), which contained YFP fused to the N-terminus
of Brg1, and cloning it into AgeI-BamHI-digested pCR3.1-Brg1 for each Brg1
sequence.
The inducible pBabe vector was generated by amplifying the LoxP-mCherry
sequence using primers listed in Supplementary Table 2 from the vector
hsp70l-loxP-mCherry-STOP-loxP-H2B-GFP_cryaa-cerulean46, digesting with
EcoRI/BglII, and ligating it and an additional LoxP site with a short polylinker
generated by two overlapping oligonucleotides (Supplementary Table 2) into the
EcoRI-SalI site of pBabe-puro using a three-way ligation. The resulting vector was
cut with AgeI and PmeI as was the pCR3.1-YFP-Brg1, and the YFP-Brg1 fragment
was ligated in.
pBABE FLAG-CAIN was created using primers containing the FLAG sequence
and homology to mouse CAIN (Supplementary Table 2) to amplify CAIN from the
BF10 plasmid20 (gift of Grace Pavlath) and cloned into the SalI and EcoRI sites of
pBabe-puro, which was used for C2C12 experiments, or pBabe-blastocydin, which
was used for primary myoblast experiments.
shRNA sequences that targeted both isoforms of PKCb are listed in
Supplementary Table 2. The sequences were cloned into pENTR/pTERþ (ref. 47)
and then introduced to pLenti x2 DEST (puro)47 via recombination.
Recombination was performed using the LR clonase mix according to the
manufacturer’s instructions (Invitrogen).
Cell culture. C2C12 cells were purchased from American Type Culture Collection
(CRL-1772). Differentiation of C2C12 cells was initiated by plating 4 104 or
1 105 cells in 12- or 24-well plates, respectively, in DMEM media containing 10%
fetal bovine serum. After 48 h, cells reached confluence, the media was changed to
DMEM containing 2% horse serum, and the cells were allowed to differentiate for
48 h, except where noted. FK-506 (Cayman Chemical) was added to the culture at
24 h after plating and included in the differentiation media at 500 nM. Go6976
(CalBiochem) was added to the differentiation media at a concentration of 500 nM.
Retrovirus was produced as previously described48. Briefly, 10 mg of DNA for
each construct were transfected into Bosc23 cells49 using Lipofectamine 2,000
(Invitrogen). The viral supernatant was collected after 48 h and filtered through a
0.45mm syringe filter (Millipore). C2C12 cells were infected with retrovirus in
the presence of 8 mgml 1 polybrene and selected for 2 days with 1 mgml 1
puromycin (Invitrogen). Surviving cells were then plated and differentiated as
described above.
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Figure 5 | PKC phosphorylation of Brg1 controls differentiation. (a) H & E staining of primary myoblasts differentiated for 4 days shows that addition
of Ad-Cre and DMSO (left column) resulted in shortened myotubes only in the cells where endogenous Brg1 was replaced with phosphomimetic Brg1
(SE-Brg1; middle row, arrowheads). When differentiated in the presence of CsA (right column), Ad-Cre-treated cells expressing wild type or SE-Brg1
differentiated into shortened myotubes (arrowheads) with fewer nuclei than their untreated counterparts, whereas cells expressing non-phosphorylatable
Brg1 (SA-Brg1) were resistant to the effects of CsA and showed elongated myotubes, with similar nuclear content to the untreated cells. Size bars, 100mm.
(b) Summary of median nuclei number across multiple experiments and clones. WT-Brg1 data are the summary of one clone and three independent trials,
SE-Brg1 is summary of two clones with three independent trials each, and SA-Brg1 is three clones with two independent trials each. 50 or more myotubes
were counted in each sample of each trial. *P¼0.034, **P¼0.0018 by two-tailed t-test; NS, not significant. (c) A model showing the role of calcium-
dependent phosphorylation in regulating chromatin remodelling. In sub-confluent, proliferating myoblasts, calcineurin is weakly bound to chromatin,
probably through interaction with an as yet unknown factor, whereas SWI/SNF enzyme is bound by PKCbI, not in association with the chromosome. Once
differentiation begins, SWI/SNF begins to be associated with the chromatin along with PKCbI. Within 1.5 h, there is a significant decrease in PKCbI
association with the promoter, and a significant increase in calcineurin and Brg1 association with the promoter. This structure is stable and results in
chromatin remodelling, leading to gene expression.
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shRNA-expressing lentivirus was produced as described47. Briefly, the lentiviral
construct DNA was co-transfected with the pLP1, pLP2 and pVSVG packaging
vectors into 293T cells (American Type Culture Collection; CRL-3216) with
Lipofectamine 2,000 reagent (Invitrogen). The viral supernatant was collected after
48 h and filtered through a 0.45-mm syringe filter (Millipore). C2C12 cells were
infected with lentivirus and selected for 2 days with 1 mgml 1 puromycin.
Surviving cells were then plated and differentiated in the presence or absence of
FK506 as described above.
Mice were housed in the animal care facility at the University of Massachusetts
Medical School (Worcester, MA, USA) in accordance with the Institutional Animal
Care and Use Committee guidelines. Mouse satellite cells were purified from total
leg muscle from 3- to 6–week-old male and female Brg1 conditional mice11 by
differential plating following Purcol sedimentation as previously described50.
Briefly, excised muscle tissue was rinsed with Hank’s Balanced Salt Solution (HBSS;
Life Technologies), sliced into small pieces and incubated with 0.1% Pronase in
HBSS at 37 C for 60min. The cell suspension was filtered using a 100-mm cell sieve
and resuspended in 3ml of growth media containing a 1:1 mix of DMEM and F-10
supplemented with 20% fetal bovine serum, 2% Chick Embryo Extract (Sera
Laboratories) and 25 ngml 1 recombinant basic FGF (Millipore). Cells were
filtered again using a 40-mm cell sieve and centrifuged at 1,000g for 1min at room
temperature. The cells were placed in the top of the Percoll gradient (35 and 70%)
and centrifuged 20min at 1,850g at room temperature. The population of
myoblasts contained in the lower interface of the 70% Percoll fraction was washed
with HBSS, centrifuged 5min at 1,000g, and resuspended in growth media for
plating. Isolated cells were grown and differentiated on plates coated overnight in
0.02% collagen (Advanced BioMatrix). Cells were differentiated in 2% horse serum
for up to 4 days.
For retrovirus infection, retrovirus was concentrated using Retro-X
concentrator (Clontech) and cells were infected in 8 mgml 1 polybrene at a
multiplicity of infection (MOI)o1 and selected with 1 mgml 1 puromycin. For
clone isolation, after 2 days of puromycin selection, cells were replated at low
density and allowed to grow for 1 week. mCherry-expressing colonies were picked
using cloning rings and transferred to collagen-coated wells of 96-well plates.
Media were changed every other day, and cells were transferred to a new collagen-
coated well every 5 days, choosing a dish size appropriate for the number of cells.
Once there were sufficient cells to reach 50% confluence on a 60-mm dish, cells
were tested for differentiation and transgene expression. To make CAIN-expressing
cells and pBABE controls, retrovirus was produced as described above and clones
were infected as described. After 24 h of infection, cells were selected for 4 days
using 4 mgml 1 blastocidin, then treated with adenovirus as described below.
Adenovirus for expression of Cre-recombinase (Ad-Cre; University of Iowa Gene
Transfer Vector Core)51 was administered at an MOI of 50. Clones were chosen
based on 499% of the cells expressing YFP-Brg1 in Cre-treated cells and a fusion
index near 100% in cells not treated with Cre recombinase. For differentiation, 2
days following Ad-Cre treatment, cells were re-plated such that they were 50%
confluent at the start of differentiation. CsA (Cell Signaling) was added at a
concentration of 2 mM 2 days before induction with CsA-containing differentiation
media. Go6976 was added at a concentration of 500 nM 24 h after plating.
Immunocytochemistry. Cells grown on 12- or 24-well plates were stained with
anti-myosin heavy chain (MF20) or anti-myogenin (F5D) antibodies obtained as
hybridoma supernatants from the Developmental Studies Hybridoma Bank.
After differentiation, cells were fixed in formalin, then incubated overnight with
hybridoma supernatant at a 1:100 dilution along with 5% horse serum, 0.2% Triton
X-100 in 1 PBS. Secondary antibody binding and HRP staining were performed
with the ABC anti-mouse kit (Vector Labs) according to the manufacturer’s
protocol.
Immunofluorescence for MHC and myogenin was performed as described
above, except that the antibodies were used at a 1:10 dilution, and secondary
detection was accomplished using an Alexa-Fluor 488-labelled secondary antibody
(1:500; Invitrogen). Cells were counterstained with 4,6-diamidino-2-phenylindole.
Mouse monoclonal antibodies against PKCa, PKCbI and PKCg (H7, E3 and D4,
respectively) were obtained from Santa Cruz and used at a 1:100 dilution. For
counting myogenin-positive and 4,6-diamidino-2-phenylindole-stained nuclei, five
separate fields were imaged for each of three data points per condition, and
counting was done automatically using CellProfiler (http://www.cellprofiler.org/).
Proximity ligation assay was performed using DuoLink Mouse Plus and Rabbit
Minus secondary antibodies and staining kit (O-Link Biosciences) using antibodies
against Brg1 (1:100 dilution; H-88, Santa Cruz), and PKCbI (1:100 dilution;
sc-8049, Santa Cruz), following the manufacturer’s instructions. As a control,
mouse anti-MyoD (1:100 dilution; Abcam) and rabbit anti-HDAC2 (1:100 dilution;
Zymed) were used to quantify the MyoD/HDAC2 interaction52–54.
Western blots and co-IP. Scraped cells were washed with PBS and solubilized in
RIPA buffer (10mM piperazine-N,N0-bis(2-ethanesulfonic acid), pH 7.4, 150mM
NaCl, 2mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate and 10%
glycerol) containing Complete Mini protease inhibitor (Roche). Equivalent
amounts of each extract were boiled in SDS-sample buffer and subjected to
SDS–polyacrylamide gel electrophoresis. The resolved proteins were transferred to
a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) and incubated with
antibodies against proteins of interest, followed by species-appropriate peroxidase-
conjugated antibodies (1:1,000 dilution; Pierce) and chemiluminescent detection as
directed by the manufacturer (ECL PLUS; GE Healthcare). Antibodies used
included myosin heavy chain (1:100 dilution; Developmental Studies Hybridoma
Bank), GST (1:500 dilution; Invitrogen), FLAG (1:1,000 dilution25), PKCbI (1:1,000
dilution; sc-8049, Santa Cruz) and mouse anti-GAPDH-Peroxidase conjugated
(1:1,000 dilution; G9295, Sigma-Aldrich).
For the co-IP experiments, C2C12 cells were differentiated in media containing
2% horse serum for 24 h. Monolayers were washed three times in PBS and
resuspended in lysis buffer (25mM Tris, pH 7.5, 1mM CaCl2, 150mM NaCl, 0.5%
NP40) and homogenized by eight strokes using a glass dounce homogenizer. Cell
lysates were incubated overnight at 4 C in an orbital shaker with the following
antibodies: Brg1 antiserum55 (10ml), anti-Baf155 (15 mg; Santa Cruz), anti-
Calcineurin (10 mg; Cell Signaling Technology), anti-mouse IgG (15mg; Santa
Cruz). Samples were then incubated for 2 h at 4 C with protein A sepharose
(Invitrogen). Samples were washed three times with buffer containing 25mM Tris,
pH 7.5, 1mM CaCl2, 300mM NaCl, 0.5% NP40. Immunoprecipitated complexes
were eluted in Laemmli Buffer by boiling the samples for 10min and were analysed
by western blot as indicated above. Uncropped images are presented in
Supplementary Fig. 9.
Restriction enzyme accessibility and ligation-mediated PCR. Restriction
enzyme accessibility assay was carried out as described25,56. Briefly, cells were
washed in PBS and nuclei isolated by incubation in lysis buffer (10mM PIPES,
pH 8, 85mM KCl, 1mM CaCl2, 5% sucrose, 0.5% NP40, plus protease inhibitors
added immediately before use, including 1 mgml 1 leupeptin and 1mM
phenylmethylsulphonyl fluoride) followed by centrifugation at 300g for 2min at
4 C. Nuclei were then incubated with PvuII (NEB) in the appropriate restriction
buffer. Cutting was assayed by ligating a linker fragment, followed by SYBR green
quantitative PCR (ABI) using primers against the linker and the PvuII site in the
myogenin promoter25,56.
ChIP assays. ChIP assays using cultured C2C12 cells were performed as
described57,58. Briefly, cells were cross-linked with 1% formaldehyde and lysed
in buffer containing 1% SDS, 10mM EDTA, pH 8, and 50mM Tris-HCl, pH 8,
with Complete Mini-Protease inhibitor (Roche). After sonication, chromatin was
pre-cleared for 1 h with protein A-agarose beads blocked with salmon sperm
DNA (Millipore). Cell lysates were incubated overnight with antibodies against
Pan-Calcineurin A (10mg; Cell Signaling Technology, 2,614) or PKCbI (10mg;
Santa Cruz, sc-8,049), polyclonal rabbit antisera against Brg1 (ref. 55; 10 ml) or
normal rabbit IgG (15 mg; Santa Cruz, sc-3888) and immunoprecipitated material
was collected with Magna ChIP Protein AþG Magnetic Beads (Millipore).
Cross-linking was reversed, and DNA was purified using ChIP DNA Clean &
Concentrator Columns (Zymo Research). Quantitative PCR utilized Fast SYBR
green master mix on the ABI StepOne Plus Sequence Detection System.
Quantification was performed using the comparative Ct method to obtain the
percent of total input DNA pulled down by each antibody. The value for each
antibody was divided by the amount precipitated by the amount of DNA
precipitated by normal IgG in the same experiment. To ascertain the statistical
significance of binding by the studied factors, amounts of DNA pulled down by the
antibody was paired with the IgG control that was performed alongside the tested
antibody, and three to six independent results were pooled for a pairwise Student’s
t-test. To test for significant changes in binding, replicate values of the antibody
divided by the IgG control were subjected to a Student’s t-test. Re-ChIP, or
sequential ChIP, experiments were performed as described59. Briefly, after
incubating the samples with the first antibody of interest and collecting
immunoprecipitated material with magnetic beads, the samples were incubated
with an equal volume of 10mM dithiothreitol for 30min at 37 C. The supernatant
was used for the second immunoprecipitation by adding the second antibody of
interest and incubating as with the first antibody. IgG substituted as the second
antibody as a control. Quantification and statistical tests were done as described
above.
In-vitro phosphorylation assays. Baculovirus produced recombinant FLAG-
tagged BRG1 was purified10. Purified recombinant PKC and calcineurin were
obtained from Sigma, and PKC activator was obtained from Millipore. PKC was
incubated for 30min with equal amounts of rBRG1 in the presence of PKC
activator that had been sonicated for 1min and 25 mM ATP containing
32P-labelled ATP. After incubation, samples were mixed with loading buffer and
electrophoresed, then transferred to PVDF membrane (Bio-Rad). After exposure
to a phosphorimaging plate, the membrane was developed using anti-FLAG
antisera25 at a 1:1,000 dilution.
GST–Brg1 fragments were produced in BL-21 E. coli by induction with 0.5mM
isopropyl-b-D-thiogalactoside for 4 h. Bacterial pellets were sonicated and bound to
GST-agarose beads (Pierce) in 1 PBS with protease inhibitors (Roche), followed
by three washes in 1 PBS and elution with 20mM reduced glutathione in 50mM
Tris, pH 8.1. For each mutant, 100 ng of purified protein was added to the
PKC reaction described above. Owing to the presence of a co-migrating PKC
auto-phosphorylation band, the C-terminal fragment (Supplementary Fig. 3d) was
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rebound to GST beads after kinase treatment and washed with three times with
1 PBS, followed by elution in loading buffer. The reactions were run on an
SDS–PAGE gel and transferred to PVDF, which was exposed to a
phosphorimaging plate, then developed using an anti-GST antibody (1:500
dilution; Invitrogen). Secondary staining was done using AF546–labelled anti-
rabbit antibody (1:1,000 dilution; Invitrogen), and blots were scanned using a
Typhoon laser imager (Molecular Dynamics). GST western and phosphorimaging
was quantified using ImageQuant (Molecular Dynamics) and the phosphorimage
signal was normalized to the GST signal. Uncropped images are presented in
Supplementary Fig. 9.
Brg1 purification for MS. Brg1 was purified from 15 15 cm plates of C2C12 cells
that had been differentiated for 24 h. Cell pellets were sonicated in SDS-lysis
buffer (50mM Tris, pH 8.1, 10mM EDTA, 1% SDS), then diluted in IP buffer
(0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris, pH 8.1, 167mM
NaCl). Brg1 was purified using an antiserum against the N-terminus25 bound to
protein A beads (Millipore), followed by washes in Buffer A (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris, pH 8.1, 150mM NaCl), Buffer B (Same as Buffer
A, but 500mM NaCl), Buffer C (0.25M LiCl, 1% NP-40, 1% sodium deoxycholate,
1mM EDTA, 10mM Tris, pH 8.1) and TE (10mM Tris pH 8.0, 1mM EDTA).
All buffers contained protease and phosphatase inhibitors (Roche). Brg1 was then
eluted in SDS-loading buffer, submitted to SDS–PAGE followed by Coomassie
staining, and the Brg1 band was cut out of the gel. BSA was run for quantitation.
B800 ng of Brg1 was purified.
In gel digestion of Brg1. Gel slices were cut into 1 1mm2 pieces and placed in
1.5ml eppendorf tubes with 1ml of water for 1 h. The water was removed and 50 ml
of 250mM ammonium bicarbonate was added. For reduction, 5 ml of a 45mM
solution of 1,4 dithiothreitol was added, and the samples were incubated at 50 C
for 30min. The samples were cooled to room temperature and alkylated for 30min
with 5 ml of 100mM iodoacetamide. The gel slices were washed twice with 1ml
water aliquots. The water was removed, 1ml of 50:50 (50mM ammonium
bicarbonate/acetonitrile) was placed in each tube, and samples were incubated at
room temperature for 1 h. The solution was then removed and 200ml of acetonitrile
was added to each tube, at which point the gels slices turned opaque white. The
acetonitrile was removed and gel slices were further dried in a Speed Vac. Gel slices
were rehydrated in 50 ml of 2 ng ml 1 trypsin (Sigma) in 0.01% ProteaseMAX
Surfactant (Promega)/50mM ammonium bicarbonate. An additional aliquot of
50mM ammonium bicarbonate was added to fully submerge the gel slices. Samples
were incubated at 37 C for 21 h. The supernatant of each sample was then
removed and placed in a new 1.5-ml eppendorf tube. Gel slices were further
dehydrated with 100ml of 80:20 (acetonitrile/1% formic acid). The extract was
combined with the supernatants of each sample. The samples were then dried in a
Speed Vac.
Isobaric labelling and MS analysis. Brg1 purified from either DMSO- or FK506-
treated cells was trypsin digested, and each sample was split into two equal aliquots
and labelled with a unique iTRAQ label (Invitrogen) following the manufacturer’s
instructions. One aliquot from each of the DMSO- or FK506-treated samples was
treated for 3 h in 2U shrimp alkaline phosphatase (Promega) plus 2U calf intestine
phosphatase (NEB) in CIP Buffer 3 (NEB), whereas the other half of each sample
was treated in buffer alone. Samples were then purified using C20 resin, eluted in
80% acetonitrile, 0.1% trifluoroacetic acid (TFA), then dried and resuspended in
water. Before analysis, samples were mixed together and were spiked with 100 fmol
of pre-digested yeast alcohol dehydrogenase (ALDH) as an internal standard. Gel
extracted tryptic peptides were injected using a NanoAquity auto sampler onto a
Symmetry C18 trapping cartridge (180 mm i.d.  2 cm length; Waters, Inc.) at a
flow rate of 5 ml min 1 for 3min. Next, peptides were separated by in-line gradient
elution onto a 75mm i.d.  10 cm column packed with BEH 130 Stationary phase
(Waters), 1.7 mm particle size, at a flow rate of 300 nlmin 1 using a linear gradient
from 2 to 40% B over 60min (A¼ 0.1% formic acid in water, B¼ 0.1% formic acid
in acetonitrile). The Q-Tof Premier (Waters, Inc.) was operated in the LC/MSE
mode of acquisition, where alternating 2 s scans of low (4V) or high (15 40V)
collision energies are used to generate either intact peptide ions (low energy) or
peptide product ions (high energy). Each raw data file was processed using
ProteinLynx Global Server (PLGS) V2.3 software (Waters, Inc.) to generate charge
state reduced and deisotoped precursor mass lists as well as associated product ion
mass lists for subsequent protein identification and quantification. Each processed
file was searched against the Uniprot/Swissprot databases using the IDENTITYE
database search algorithm within PLGS V2.4. Parameters were set to: peptide
tolerance¼ 15 p.p.m.; fragment tolerance¼ 30 p.p.m.; minimum fragment ion
matches per peptide¼ 3; minimum fragment ion matches per protein¼ 7;
minimum peptide ion matches per protein¼ 2; primary digest reagent¼ trypsin;
missed cleavages¼ 2; cysteine carbamidomethylation as fixed modification
and methionine oxidation, asparagine and glutamine deamination as variable
modifications. A false positive rate of 4% was allowed, and calculated by the
appearance in search results of peptides from a randomized protein database60.
Each sample was injected in triplicate and the data were pooled, and the expected
fragments from iTRAQ labels were extracted. Peptides were included in study if
there was a ladder score of 410, if they were identified as having an isobaric tag
and if all four isobaric label fragments were present.
Peptide relative quantification. Values for the contribution of each isobaric tag
were extracted from processed raw files and matched to the peptide identification.
For each peptide, the ion intensity of the isobaric tag corresponding to the mock-
dephosphorylated samples was divided by those of the in-vitro dephosphorylated
samples. To normalize for errors in sample mixing, peptides identified as not
containing serine, threonine or tyrosine (non-STY) were averaged for each of the
FK506- or DMSO-treated samples. All peptides were then normalized to these
values independently for the values arising from FK506- or DMSO-treated samples.
To examine potential kinase sites, data from peptides containing the same S,
T or Y residues were pooled, and an average was generated for each set of S, T or Y
residues (Supplementary Table 1). The Brg1 protein sequence was submitted to
NetPhosK to identify potential kinase sites using a cutoff value 0.4. For each kinase,
peptides were scored as targets if they contained a serine or threonine scoring
above this threshold. Logistic regression was then used to determine the association
between the presence of a kinase site and the ratio of isobaric labels from the
FK506-treated samples.
TiO2 phosphopeptide enrichment. Phosphopeptides were enriched using a
NuTip TiO2 micropipette tip (Glygen Corp.). The dried peptide digest was
dissolved in 10 ml of binding solvent (75:19:6¼ acetonitrile/water/TFA) and
on-third was used for enrichment. A 1–10 ml TiO2 NuTip was washed two times
with 10ml aliquots of binding solvent. Phosphopeptides were bound by repetitive
pipetting (20 times) of the 10 ml sample volume. The NuTip was then washed five
times with binding solvent and then five times with 0.1% TFA. Phosphopeptides
were then eluted in a separate tube with a 10-ml volume of 6% NH4OH after
repetitive pipetting (10 times). A 5-ml aliquot of 5% TFA was then added and the
phosphopeptides were further concentrated in a Speed Vac before injection on the
LC-MS/MS system.
LC-MS/MS on Orbitrap Velos. Tryptic peptides were dissolved in 20 ml of 0.1%
TFA and a 3.5-ml aliquot was directly injected onto a custom packed trap column
(2 cm 100mm C18). Peptides were then eluted and sprayed from a custom
packed emitter (75 mM 25 cm C18) with a linear gradient from 100% solvent A
(0.1% formic acid in 5% acetonitrile) to 35% solvent B (0.1% formic acid in
acetonitrile) in 90min at a flow rate of 300 nlmin 1 on a Proxeon Easy nanoLC
system directly coupled to a LTQ Orbitrap Velos mass spectrometer (Thermo
Scientific). Data-dependent acquisitions were set up according to an experiment
where full MS scans from 350 to 2,000m/z were acquired in the Orbitrap at a
resolution of 60,000 followed by 10 MS/MS scans acquired in the LTQ ion trap
instrument. The raw data files were processed with Extract_ MSN (Thermo
Scientific) into peak lists and then searched against the Mouse index of the
SwissProt database using the Mascot Search engine ver. 2.3 (Matrixsciences, Ltd.).
Parent mass tolerances were set to 10 p.p.m. and fragment mass tolerances were set
to 0.5Da. Data were searched for tryptic peptides, with a maximum of two missed
cleavages and instrument mode set to electrospray ionization fourier transform
ion cyclotron resonance (ESI-FTICR). The variable modifications of acetyl
(protein N-term), STY phosphorylation, pyro glutamic for N-term glutamine,
carbamidomethylation of cysteine and oxidation of methionine were used. Mascot
search results were loaded into the Scaffold software (Proteome Software, Inc.)
to compare sample results.
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